ARIA-E

1. APOE raises the risk of ARIA-E in humans (about 40% risk).

   “APOE ε4 carriers, with homozygotes having about a 40% risk of ARIA‐E”

   ReviewAPOE ε4 homozygotes

   Safety and Efficacy of Concomitant Intensive Systolic Blood Pressure Control with Anti‐amyloid Monoclonal Antibodies in Reducing Amyloid Related Imaging Abnormalities

   AAIC 2025 abstract·23 Dec 2025

More on APOE

1. Antihypertensive medication lowers the risk of ARIA-E in humans (-40% risk).

   “baseline antihypertensive medication use reduced this risk by 40%”

   Reviewin donanemab trials

   Safety and Efficacy of Concomitant Intensive Systolic Blood Pressure Control with Anti‐amyloid Monoclonal Antibodies in Reducing Amyloid Related Imaging Abnormalities

   AAIC 2025 abstract·23 Dec 2025

More on Antihypertensive medication

1. High blood pressure raises the risk of ARIA-E in humans (+70% risk).

   “baseline mean arterial pressure (MAP) >107 mm Hg, roughly equivalent to a BP of ∼140/90, was associated with a 70% increased risk of ARIA‐E”

   Reviewbaseline mean arterial pressure >107 mm Hg in donanemab trials

   Safety and Efficacy of Concomitant Intensive Systolic Blood Pressure Control with Anti‐amyloid Monoclonal Antibodies in Reducing Amyloid Related Imaging Abnormalities

   AAIC 2025 abstract·23 Dec 2025